Linked Life Data

11249763

Source:http://linkedlifedata.com/resource/pubmed/id/11249763

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2001-3-15
pubmed:abstractText
Avigen has developed a recombinant adeno-associated viral vector expressing human blood-coagulation Factor IX (F.IX) for the potential treatment of hemophilia B. In a phase I clinical trial being conducted at The Children's Hospital of Philadelphia and Stanford University Medical Center, the vector, AAV-CMV-hF.IX (Coagulin-B), was injected at a low dose into three patients with severe hemophilia B. No evidence of toxicity, germline transmission of vector sequences, or formation of inhibitory antibodies against F.IX was observed, and in two of the three patients there was an indication of a modest clinical response.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1464-8431
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
601-6
pubmed:dateRevised
2006-4-21
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
pubmed:affiliation
Department of Biochemistry, Royal Holloway College, University of London, Egham, Surrey, TW20 OEX, UK. s.fabb@rhbnc.ac.uk
pubmed:publicationType
Journal Article, Clinical Trial, Review, Multicenter Study, Clinical Trial, Phase I